After acute myocardial infarction, ventricular remodeling is characterized by changes at the molecular, structural, geometrical and functional level that determine progression to heart failure. Inflammation plays a key role in wound healing and scar formation, affecting ventricular remodeling. Several, rather different, components of the inflammatory response were studied as biomarkers in ST-elevation acute myocardial infarction. Widely available and inexpensive tests, such as leukocyte count at admission, as well as more sophisticated immunoassays provide powerful predictors of adverse outcome in patients with ST-elevation acute myocardial infarction. We review the value of inflammatory markers in ST-elevation acute myocardial infarction and their association with ventricular remodeling, heart failure and sudden death. In conclusion, the use of these biomarkers may identify subjects at greater risk of adverse events and perhaps provide an insight into the mechanisms of disease progression.
National Heart Lung and Blood Institute. Morbidity and mortality: 2012 chart book on cardiovascular and lung diseases. Bethesda, MD: NIH, 2012.
2.
O’GaraPTKushnerFGAscheimDD. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013; 127(4): e362–e425.
3.
StegPGJamesSKAtarD. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J2012; 33(20): 2569–2619.
4.
PfefferJMPfefferMABraunwaldE. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res1985; 57: 84–95.
5.
CohnJNFerrariRSharpeN. Cardiac remodeling—concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol2000; 35(3): 569–582.
6.
St. John SuttonMPfefferMPlappertT. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation1994; 89(1): 68–75.
7.
WhiteHNorrisRBrownM. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation1987; 76(1): 44–51.
8.
JessupMBrozenaS. Heart failure. N Engl J Med2003; 348(20): 2007–2018.
9.
GoldbergRJSpencerFAYarzebskiJ. A 25-year perspective into the changing landscape of patients hospitalized with acute myocardial infarction (the Worcester Heart Attack Study). Am J Cardiol2004; 94(11): 1373–1378.
10.
VelagaletiRSPencinaMJMurabitoJM. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation2008; 118(20): 2057–2062.
11.
ChewDPHuynhLTLiewD. Potential survival gains in the treatment of myocardial infarction. Heart2009; 95(22): 1844–1850.
12.
EapenZJTangWHWFelkerGM. Defining heart failure end points in ST-segment elevation myocardial infarction trials: Integrating past experiences to chart a path forward. Circ Cardiovasc Qual Outcomes2012; 5(4): 594–600.
13.
ChenJHsiehAF-CDharmarajanK. National trends in heart failure hospitalization after acute myocardial infarction for medicare beneficiaries: 1998–2010. Circulation2013; 128(24): 2577–2584.
14.
HoebersLClaessenB. Primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. EuroIntervention2014; 10(1): 90–96.
15.
FrangogiannisNGSmithCWEntmanML. The inflammatory response in myocardial infarction. Cardiovasc Res2002; 53(1): 31–47.
16.
FrangogiannisNG. The immune system and cardiac repair. Pharmacol Res2008; 58(2): 88–111.
17.
FrangogiannisNG. Regulation of the inflammatory response in cardiac repair. Circ Res2012; 110(1): 159–173.
SeropianIToldoSVan TassellB. Anti-inflammatory strategies for ST-elevation acute myocardial infarction ventricular remodeling. J Am Coll Cardiol2014; 63(16): 1593–1603.
20.
Van TassellBWToldoSMezzaromaE. Targeting interleukin-1 in heart disease. Circulation2013; 128(17): 1910–1923.
21.
AbbateAVan TassellBWBiondi-ZoccaiG. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the virginia commonwealth university-anakinra remodeling trial (2) (VCU-ART2) Pilot Study]. Am J Cardiol2013; 111(10): 1394–1400.
22.
ØrnSManhenkeCUelandT. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J2009; 30(10): 1180–1186.
23.
SuleimanMKhatibRAgmonY. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol2006; 47(5): 962–968.
24.
BursiFWestonSAKillianJM. C-reactive protein and heart failure after myocardial infarction in the community. Am J Med2006; 120(7): 616–622.
25.
MatherANFairbairnTAArtisNJ. Relationship of cardiac biomarkers and reversible and irreversible myocardial injury following acute myocardial infarction as determined by cardiovascular magnetic resonance. Int J Cardiol2013; 166(2): 458–464.
26.
ModanBSchorSShaniM. Acute myocardial infarction. Prognostic value of white blood cell count and blood glucose level. JAMA1975; 233(3): 266–267.
27.
MenonVLessardDYarzebskiJ. Leukocytosis and adverse hospital outcomes after acute myocardial infarction. Am J Cardiol2003; 92(4): 368–372.
28.
QianGWuCChenY-D. Predictive factors of cardiac rupture in patients with ST-elevation myocardial infarction. J Zhejiang Univ Sci B2014; 15(12): 1048–1054.
29.
ChungSSongYBHahnJ-Y. Impact of white blood cell count on myocardial salvage, infarct size, and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A magnetic resonance imaging study. Int J Cardiovasc Imaging2014; 30(1): 129–136.
30.
BarronHVCannonCPMurphySA. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: A thrombolysis in myocardial infarction 10 substudy. Circulation2000; 102(19): 2329–2334.
31.
PalmeriniTMehranRDangasG. Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: Analysis from the harmonizing outcome with revascularization and Stent in Acute Myocardial Infarction trial. Circulation2011; 123(24): 2829–2837.
32.
PalmeriniTBrenerSJGenereuxP. Relation between white blood cell count and final infarct size in patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention (from the INFUSE AMI Trial). Am J Cardiol2013; 112(12): 1860–1866.
33.
KyneLHausdorffJMKnightE. Neutrophilia and congestive heart failure after acute myocardial infarction. Am Heart J2000; 139(1): 94–100.
34.
TamuraAWatanabeTNasuM. Association between neutrophil counts on admission and left ventricular function in patients successfully anterior wall acute myocardial infarction. Am J Cardiol2001; 88(01): 678–680.
35.
HusserOBodiVSanchisJ. White blood cell subtypes after STEMI: Temporal evolution, association with cardiovascular magnetic resonance—Derived infarct size and impact on outcome. Inflammation2011; 34(2): 73–84.
36.
MaekawaYAnzaiTYoshikawaT. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: A possible role for left ventricular remodeling. J Am Coll Cardiol2002; 39(2): 241–246.
37.
TsujiokaHImanishiTIkejimaH. Post-reperfusion enhancement of CD14+CD16− monocytes and microvascular obstruction in ST-segment elevation acute myocardial infarction. Circ J2010; 74(6): 1175–1182.
38.
IkejimaHImanishiTTsujiokaH. Effect of human peripheral monocyte subsets on coronary flow reserve in infarct-related artery in patients with primary anterior acute myocardial infarction. Clin Exp Pharmacol Physiol2010; 37(4): 453–459.
39.
TsujiokaHImanishiTIkejimaH. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol2009; 37(2): 130–138.
40.
TappLDShantsilaEWrigleyBJ. The CD14++CD16+ monocyte subset and monocyte–platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost2009; 10(7): 1231–1241.
41.
WrigleyBJShantsilaETappLD. CD14++CD16+ monocytes in patients with acute ischaemic heart failure. Eur J Clin Invest2013; 10(2): 121–130.
42.
BodíVSanchisJNúñezJ. Post-reperfusion lymphopenia and microvascular obstruction in ST-segment elevation acute myocardial infarction. Rev Esp Cardiol2009; 62(10): 1109–1117.
NúñezJNúñezEBodíV. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol2008; 101(6): 747–752.
45.
ChoKHJeongMHAhmedK. Value of early risk stratification using hemoglobin level and neutrophil-to-lymphocyte ratio in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol2011; 107(6): 849–856.
46.
AkpekMKayaMGLamYY. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol2011; 110(5): 621–627.
47.
SenNAfsarBOzcanF. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis2013; 228(1): 203–210.
48.
SawantAAdhikariP. Neutrophil to lymphocyte ratio predicts short and long term mortality following revascularization therapy for ST elevation myocardial infarction. Cardiol J2013; 21(5): 500–508.
49.
ArbelYShachamYZiv-BaranT. Higher neutrophil/lymphocyte ratio is related to lower ejection fraction and higher long-term all-cause mortality in ST-elevation myocardial infarction patients. Can J Cardiol2014; 30(10): 1177–1182.
50.
GhaffariSNadiriMPourafkariL. The predictive value of total neutrophil count and neutrophil/lymphocyte ratio in predicting in-hospital mortality and complications after STEMI. J Thorac Cardiovasc Surg2014; 6(1): 35–41.
51.
HeJLiJWangYHaoP. Neutrophil-to-lymphocyte ratio (NLR) predicts mortality and adverse-outcomes after ST-segment elevation myocardial infarction in Chinese people. Int J Clin Exp Pathol2014; 7(7): 4045–4056.
52.
HanY-CYangT-HKimD-I. Neutrophil to lymphocyte ratio predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Korean Circ J2013; 43(2): 93–99.
53.
NiccoliGBurzottaFGaliutoL. Myocardial no-reflow in humans. J Am Coll Cardiol2011; 54(4): 281–292.
54.
SoyluKYukselSGulelO. The relationship of coronary flow to neutrophil/lymphocyte ratio in patients undergoing primary percutaneous coronary intervention. J Thorac Dis2013; 5(3): 258–264.
55.
DoganMAkyelABilginM. Can admission neutrophil to lymphocyte ratio predict infarct-related artery patency in ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost2013.
56.
KurtulAMuratSNYarliogluesM. The relationship between neutrophil/lymphocyte ratio and infarct-related artery patency before mechanical reperfusion in patients with ST-elevation myocardial infarction. Coron Artery Dis2014; 25(2): 159–166.
57.
ErkolAOduncuVTuranB. Neutrophil to lymphocyte ratio in acute ST-segment elevation myocardial infarction. Am J Med Sci2014; 348(1): 37–42.
58.
AyçaBAkınFCelikO. Neutrophil to lymphocyte ratio is related to stent thrombosis and high mortality in patients with acute myocardial infarction. Angiology2014.
59.
KayaAKayaYTopçuS. Neutrophil-to-lymphocyte ratio predicts contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology2014; 65(1): 51–56.
60.
YilmazADietelBCichaI. Emergence of dendritic cells in the myocardium after acute myocardial infarction – Implications for inflammatory myocardial damage. Int J Biomed Sci2010; 6(1): 27–36.
61.
KretzschmarDBetgeSWindischA. Recruitment of circulating dendritic cell precursors into the infarcted myocardium and pro-inflammatory response in acute myocardial infarction. Clin Sci2012; 123(6): 387–398.
62.
KoflerSSisicZShvetsN. Expression of circulatory dendritic cells and regulatory T-cells in patients with different subsets of coronary artery disease. J Cardiovasc Pharmacol2012; 57(5): 542–549.
63.
YilmazAWeberJCichaI. Decrease in circulating myeloid dendritic cell precursors in coronary artery disease. J Am Coll Cardiol2012; 48(1): 70–80.
64.
MontagnanaMCervellinG. The role of red blood cell distribution width in cardiovascular and thrombotic disorders. Clin Chem Lab Med2012; 50(4): 635–641.
65.
KarabulutAUyarelHUzunlarB. Elevated red cell distribution width level predicts worse postinterventional thrombolysis in myocardial infarction flow reflecting abnormal reperfusion in acute myocardial infarction treated with a primary coronary intervention. Coron Artery Dis2012; 23(1): 68–72.
66.
SangoiMBDa SilvaSHda SilvaJEP. Relation between red blood cell distribution width and mortality after acute myocardial infarction. Int J Cardiol2011; 146(2): 450–454.
67.
İlhanEGüvençTSAltayS. Predictive value of red cell distribution width in intrahospital mortality and postintervention thrombolysis in myocardial infarction flow in patients with acute anterior myocardial infarction. Coron Artery Dis2012; 23(7): 450–454.
68.
DabbahSHammermanHMarkiewiczW. Relation between red cell distribution width and clinical outcomes after acute myocardial infarction. Am J Cardiol2010; 105(3): 312–317.
69.
UyarelHErgelenMCicekG. Red cell distribution width as a novel prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. Coron Artery Dis2011; 22(3): 138–144.
70.
LeeJHYangDHJangSY. Incremental predictive value of red cell distribution width for 12-month clinical outcome after acute myocardial infarction. Clin Cardiol2013; 36(6): 336–341.
71.
SunXChenWSunZ. Impact of red blood cell distribution width on long-term mortality in patients with ST-elevation myocardial infarction. Cardiology2014; 128(4): 343–348.
72.
ArbelYShachamYFinkelsteinA. Red blood cell distribution width (RDW) and long-term survival in patients with ST elevation myocardial infarction. Thromb Res2014; 134(5): 976–979.
73.
MizunoAOhdeSNishizakiY. Additional value of the red blood cell distribution width to the Mehran risk score for predicting contrast-induced acute kidney injury in patients with ST-elevation acute myocardial infarction. J Cardiol2014.
74.
JakobPLandmesserU. Current status of cell-based therapy for heart failure. Curr Heart Fail Rep2012; 10(2): 165–176.
75.
WojakowskiWKuciaMKaźmierskiM. Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: Relevant reparatory mechanism?Heart2008; 10(1): 27–33.
76.
PortoIDe MariaGLLeoneAM. Endothelial progenitor cells, microvascular obstruction, and left ventricular remodeling in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol2013; 112(6): 782–791.
77.
ShintaniSMuroharaTIkedaH. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation2001; 103(23): 2776–2779.
78.
MassaMRostiVFerrarioM. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood2005; 105(1): 199–206.
79.
GrøgaardHKSolheimSLandsverkKS. Circulating CD34+ progenitor cells and growth factors in patients treated with PCI for acute myocardial infarction or stable angina pectoris. Scand J Clin Lab Invest2011; 71(4): 322–329.
80.
MarianiMDe ServiSChianeseR. Circulating CD34-positive cell number is related to effective myocardial reperfusion in acute myocardial infarction treated with primary coronary angioplasty. J Cardiovasc Med2008; 9(7): 677–682.
81.
LeoneAMRutellaSBonannoG. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J2005; 26(12): 1196–1204.
82.
WangYJohnsenHEMortensenS. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart2006; 92(6): 768–774.
83.
GaspardoneAMenghiniFMazzucaV. Progenitor cell mobilisation in patients with acute and chronic coronary artery disease. Heart2006; 92(2): 253–254.
84.
GeislerTFekecsLWursterT. Association of platelet-SDF-1 with hemodynamic function and infarct size using cardiac MR in patients with AMI. Eur J Radiol2012; 81(4): e486–e490.
85.
JeongHSHongSJParkJH. Correlation between circulating angiogenic cell mobilizations and recovery of coronary flow reserve in patients with acute myocardial infarction. Circ J2012; 76(5): 1213–1221.
86.
GrąbczewskaZDębskiRGóralczykK. Does mobilisation of CD34+ stem cells along with VEGF, angiogenin, IL-6, IL-8, and hsCRP levels allow predicting the direction of left ventricular ejection fraction and wall motion score index changes in patients with myocardial infarction?Kardiol Pol2013; 71(5): 464–471.
87.
WojakowskiWTenderaMZebzdaA. Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur Heart J2006; 27(3): 283–289.
88.
WyderkaRWojakowskiWJadczykT. Mobilization of CD34+CXCR4+ stem/progenitor cells and the parameters of left ventricular function and remodeling in 1-year follow-up of patients with acute myocardial infarction. Mediat Inflamm2012; 2012: 1–11.
89.
YuCWChoiS-CHongSJ. Cardiovascular event rates in patients with ST-elevation myocardial infarction were lower with early increases in mobilization of Oct4(high)Nanog(high) stem cells into the peripheral circulation during a 4-year follow-up. Int J Cardiol2013; 168(3): 2533–2539.
90.
ChangLYuenCSunC. Role of stromal cell-derived factor-1α, level and value of circulating interleukin-10 and endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ J2009; 73(6): 1097–1104.
91.
ChangH-WLeuSSunC-K. Level and value of circulating endothelial progenitor cells in patients with acute myocardial infarction undergoing primary coronary angioplasty: In vivo and in vitro studies. Transl Res2010; 156(4): 251–63.
92.
WernerNKosiolSSchieglT. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med2005; 353(10): 999–1007.
93.
NiccoliGDatoICreaF. Myeloperoxidase may help to differentiate coronary plaque erosion from plaque rupture in patients with acute coronary syndromes. Trends Cardiovasc Med2010; 20(8): 276–281.
94.
KhanSQKellyDQuinnP. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart2007; 93(8): 826–831.
95.
StankovicSAsaninMTrifunovicD. Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Clin Biochem2012; 45(7–8): 547–551.
96.
NilssonLHallénJAtarD. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart2012; 98(1): 31–36.
97.
Dominguez-RodriguezASamimi-FardSAbreu-GonzalezP. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am J Cardiol2008; 101(11): 1537–1540.
98.
StankovicSAsaninM. The usefulness of myeloperoxidase in prediction of in-hospital mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous. Clin Lab2011; 58(1–2): 125–131.
99.
KayaMGYalcinROkyayK. Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Tex Heart Inst J2012; 39(4): 500–506.
100.
MarshallCJNallaratnamMMocattaT. Factors influencing local and systemic levels of plasma myeloperoxidase in ST-segment elevation acute myocardial infarction. Am J Cardiol2010; 106(3): 316–322.
101.
DinarelloCA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood2011; 117(14): 3720–3732.
102.
BujakMFrangogiannisNG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp2009; 57(3): 165–176.
103.
BiasucciLMLiuzzoGFantuzziG. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation1999; 99(16): 2079–2084.
104.
GuillenIBlanesMCastellJV. Cytokine signaling during myocardial infarction : Sequential appearance of IL-1 beta and IL-6 cytokine signaling during myocardial infarction : Sequential appearance of ILAp and IL-6. Am J Physiol1995; 269(2): 229–235.
105.
ØrnSUelandTManhenkeC. Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J Intern Med2012; 272(3): 267–276.
106.
PattiGMegaSPasceriV. Interleukin-1 receptor antagonist levels correlate with extent of myocardial loss in patients with acute myocardial infarction. Clin Cardiol2005; 28(4): 193–196.
107.
ShimpoMMorrowDAWeinbergEO. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation2004; 109(18): 2186–2190.
108.
SabatineMSMorrowDAHigginsLJ. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation2008; 117(15): 1936–1944.
109.
DhillonOSNarayanHKKhanSQ. Pre-discharge risk stratification in unselected STEMI: Is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers?Int J Cardiol2013; 167(5): 2182–2188.
110.
WeirRAMillerAMMurphyGE. Serum soluble ST2: A potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol2010; 55(3): 243–250.
111.
YamamotoKRose-JohnS. Therapeutic blockade of interleukin-6 in chronic inflammatory disease. Clin Pharmacol Ther2012; 91(4): 574–576.
112.
LindmarkEDiderholmE. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease. JAMA2001; 286(17): 2107–2113.
113.
Di StefanoRDi BelloVBarsottiMC. Inflammatory markers and cardiac function in acute coronary syndrome: Difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI models. Biomed Pharmacother2009; 63(10): 773–780.
114.
HartfordMWiklundOMattsson HulténL. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol2006; 108(1): 55–62.
115.
ProndzinskyRUnverzagtSLemmH. Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol2012; 101(5): 375–384.
116.
HartfordMWiklundOMattsson HulténL. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med2007; 262(5): 526–536.
117.
ThérouxPArmstrongPWMahaffeyKW. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the COMMA trial. Eur Heart J2005; 26(19): 1964–1970.
118.
Van DiepenSNewbyLKLopesRD. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. Inflammation2013; 168(3): 2127–2133.
119.
TanJHuaQGaoJ. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol2008; 31(9): 413–418.
120.
TanJHuaQLiJ. Prognostic value of interleukin-6 during a 3-year follow-up in patients with acute ST-segment elevation myocardial infarction. Heart Vessel2009; 24(5): 329–334.
121.
KavsakPAKoDTNewmanAM. Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. Clin Chem2007; 53(12): 2112–2118.
122.
HalvorsenSSeljeflotIWeissT. Inflammatory and thrombotic markers in patients with ST-elevation myocardial infarction treated with thrombolysis and early PCI: A NORDISTEMI substudy. Thromb Res2012; 130(3): 495–500.
123.
Borrayo-SánchezG. Prognostic value of serum levels of interleukin-6 in patients with ST-segment elevation acute myocardial infarction. Cir Cir2010; (1): 25–30.
124.
OhtsukaTHamadaMInoueK. Relation of circulating interleukin-6 to left ventricular remodeling in patients with reperfused anterior myocardial infarction. Clin Cardiol2004; 27(7): 417–420.
125.
FrangogiannisNG. The mechanistic basis of infarct healing. Antioxid Redox Signal2006; 8: 1907–1939.
126.
NilssonLSzymanowskiASwahnE. Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS One2013; 8(2): e55477.
127.
KarpińskiLPłaksejRKosmalaW. Serum levels of interleukin-6, interleukin-10 and C-reactive protein in relation to left ventricular function in patients with myocardial infarction treated with primary angioplasty. Kardiolo Pol2008; 66(12): 1279–1285.
128.
Dominguez-RodriguezAAbreu-GonzalezPGarcia-GonzalezMJ. Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res2007; 121(3): 293–299.
129.
Appa FalcaoRChristopherSOddiC. Interleukin-10 in patients with ST-segment elevation myocardial infarction. Int J Cardiol2014; 172(1): e6–e8.
130.
KempfTZarbockAWideraC. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med2011; 17(5): 581–588.
EitelIBlasePAdamsV. Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: Insights from cardiovascular magnetic resonance. Heart2011; 97(8): 632–640.
133.
LinJ-FWuSHsuS-Y. Growth-differentiation factor-15 and major cardiac events. Am J Med Sci2014; 347(4): 305–311.
134.
BiasucciLM. CDC/AHA workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: Clinical use of inflammatory markers in patients with cardiovascular diseases: A background paper. Circulation2004; 110(25): e560–e567.
135.
MatsumoriAFurukawaYHashimotoT. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol1997; 29(1): 419–423.
136.
ParissisJTAdamopoulosSVenetsanouKF. Serum profiles of C-C chemokines in acute myocardial infarction: Possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res2002; 22(2): 223–229.
137.
Kobusiak-ProkopowiczMOrzeszkoJMazurG. Chemokines and left ventricular function in patients with acute myocardial infarction. Eur J Intern Med2007; 18(4): 288–294.
138.
BuyukkayaEPoyrazFKarakasMF. Usefulness of monocyte chemoattractant protein-1 to predict no-reflow and three-year mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol2013; 112(2): 187–193.
YuCLauCLaiK. Elevation of plasma level of macrophage migration inhibitory factor in patients with acute myocardial infarction. Am J Cardiol2001; 88(7): 774–777.
141.
YuC-MLaiKW-HChenY-X. Expression of macrophage migration inhibitory factor in acute ischemic myocardial injury. J Histochem Cytochem2003; 51(5): 625–631.
142.
TakahashiMNishihiraJKatsukiT. Elevation of plasma level of macrophage migration inhibitory factor in patients with acute myocardial infarction. Am J Cardiol2002; 89(2): 248–249.
143.
WhiteDAFangLChanW. Pro-inflammatory action of MIF in acute myocardial infarction via activation of peripheral blood mononuclear cells. PLoS One2013; 8(10): e76206.
144.
ChanWWhiteDAWangX-Y. Macrophage migration inhibitory factor for the early prediction of infarct size. J Am Heart Assoc2013; 2(5): e000226.
145.
SteppichBAMoogPMatissekC. Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis2007; 190(2): 443–451.
146.
StellosKRufMSopovaK. Plasma levels of stromal cell-derived factor-1 in patients with coronary artery disease: Effect of clinical presentation and cardiovascular risk factors. Atherosclerosis2011; 219(2): 913–916.
147.
YousufOMohantyBDMartinSS. High-sensitivity C-reactive protein and cardiovascular disease: A resolute belief or an elusive link?J Am Coll Cardiol2013; 62(5): 397–408.
148.
AnzaiT. Post-infarction inflammation and left ventricular remodeling: A double-edged sword. Circ J2013; 77(3): 580–587.
149.
MorishimaISoneTTsuboiH. Plasma C-reactive protein predicts left ventricular remodeling and function after a first acute anterior wall myocardial infarction treated with coronary angioplasty: Comparison with brain natriuretic peptide. Clin Cardiol2002; 25(3): 112–116.
150.
RoubilleFSamriACornilletL. Routinely-feasible multiple biomarkers score to predict prognosis after revascularized STEMI. Eur J Intern Med2010; 21(2): 131–136.
151.
AnzaiTYoshikawaTShirakiH. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation1997; 96(3): 778–784.
152.
SuleimanMAronsonDReisnerSA. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med2003; 115(9): 695–701.
153.
OhlmannPJaqueminLMorelO. Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. Am Heart J2006; 152(6): 1161–1167.
154.
SciricaBMMorrowDACannonCP. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem2007; 53(10): 1800–1807.
155.
SmitJJOttervangerJPSlingerlandRJ. Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction. Am J Cardiol2008; 101(4): 446–451.
156.
DerzhkoRPlaksejRPrzewlocka-KosmalaM. Prediction of left ventricular dysfunction progression in patients with a first ST-elevation myocardial infarction—Contribution of cystatin C assessment. Coron Artery Dis2009; 20(7): 453–461.
157.
FertinMHennacheBHamonM. Usefulness of serial assessment of B-type natriuretic peptide, troponin I, and C-reactive protein to predict left ventricular remodeling after acute myocardial infarction (from the REVE-2 study). Am J Cardiol2010; 106(10): 1410–1416.
158.
Urbano-MoralJALopez-HaldonJEFernandezM. Prognostic value of different serum biomarkers for left ventricular remodelling after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart2012; 98(15): 1153–1159.
159.
SwiatkiewiczIKozinskiMMagielskiP. Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction. Mediat Inflamm2012: 1–11.
160.
SwiatkiewiczIKozinskiMMagielskiP. Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflamm Res2012; 61(7): 725–734.
161.
VrsalovicMPintaricHBabicZ. Impact of admission anemia, C-reactive protein and mean platelet volume on short term mortality in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Clin Biochem2012; 45(16–17): 1506–1509.
162.
SchoosMMMunthe-FogLSkjoedtM-O. Association between lectin complement pathway initiators, C-reactive protein and left ventricular remodeling in myocardial infarction-a magnetic resonance study. Mol Immunol2013; 54(3–4): 408–414.
163.
MarcucciRValenteSGoriAM. Global platelet hyperreactivity and elevated C-reactive protein levels predict long term mortality in STEMI patients. Thromb Res2014; 134(4): 884–888.
164.
ShachamYLeshem-RubinowESteinvilA. High sensitive C-reactive protein and the risk of acute kidney injury among ST elevation myocardial infarction patients undergoing primary percutaneous intervention. Clin Exp Neprhol2014.
165.
BiasucciLMLiuzzoGGrilloRL. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation1999; 99(7): 855–860.
166.
PepysMBHirschfieldGMTennentGA. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature2006; 440(7088): 1217–1221.
167.
BiasucciLMBellocciFLandolinaM. Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: Results of the CAMI-GUIDE study. Eur Heart J2012; 33(11): 1344–1350.
168.
AbbateAKontosMCGrizzardJD. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol2010; 105(10): 1371.e1–1377.e1.
169.
MortonACRothmanAMGreenwoodJP. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: The MRC-ILA Heart Study. Circulation2013; 128: A14792.
170.
NairzMSonnweberTSchrollA. The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect2012; 14(3): 238–246.
171.
GaoDNingNNiuX. Erythropoietin treatment in patients with acute myocardial infarction: A meta-analysis of randomized controlled trials. Am Heart J2012; 164(5): 715.e1–727.e1.
172.
NamiuchiSKagayaYOhtaJ. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol2005; 45(9): 1406–1412.
173.
NiccoliGAndreottiFMarzoF. Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction. Eur J Clin Invest2011; 41(11): 1210–1219.
174.
SzummerKLindahlBSylvénC. Relationship of plasma erythropoietin to long-term outcome in acute coronary syndrome. Int J Cardiol2010; 143(2): 165–170.
175.
BarseghianAGawandeDBajajM. Adiponectin and vulnerable atherosclerotic plaques. J Am Coll Cardiol2011; 57(7): 761–770.
176.
KojimaSFunahashiTSakamotoT. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart2003; 89(6): 667.
177.
ChenCAsakuraMAsanumaH. Plasma adiponectin levels predict cardiovascular events in the observational Arita Cohort Study in Japan: The importance of the plasma adiponectin levels. Hypertens Res2012; 35(8): 843–848.
178.
KrasnodębskiPOpolskiGKarnafelW. Plasma adiponectin levels in acute myocardial infarction and during the postinfarction recovery period in patients with type 2 diabetes mellitus. Kardiol Pol2011; 69(9): 924–930.
179.
ShibataRNumaguchiYMatsushitaK. Usefulness of adiponectin to predict myocardial salvage following successful reperfusion in patients with acute myocardial infarction. Am J Cardiol2008; 101(12): 1712–1715.
180.
LindbergSPedersenSHMøgelvangR. Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol2012; 109(4): 492–496.
181.
WilsonSRSabatineMSWiviottSD. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J2009; 161(6): 1147–1155.
182.
PiestrzeniewiczKLuczakKGochJ. Value of blood adipose tissue hormones concentration—Adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in 1-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial. Neuro Endocrinol Lett2008; 29(4): 581–588.
183.
ReinstadlerSJKlugGFeistritzerHJ. Relation of plasma adiponectin levels and aortic stiffness after acute ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care2014; 3(1): 10–17.
184.
MoritaYMaedaKKondoT. Impact of adiponectin and leptin on long-term adverse events in Japanese patients with acute myocardial infarction. Circ J2013; 77(11): 2778–2785.
185.
ShimWMehtaALimSY. G-CSF for stem cell therapy in acute myocardial infarction: Friend or foe?Cardiovasc Res2011; 89(1): 20–30.
186.
LeoneAMRutellaSBonannoG. Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. Int J Cardiol2006; 111(2): 202–208.
187.
MaY-TFuZ-Y. Serum profiles of circulating granulocyte-macrophage colony-stimulating factor in acute myocardial infarction and relation with post-infarction left ventricular function. Chin Med J2005; 118(8): 1557–1559.
ParissisJTAdamopoulosSVenetsanouK. Plasma profiles of circulating granulocyte-macrophage colony-stimulating factor and soluble cellular adhesion molecules in acute myocardial infarction. Contribution to post-infarction left ventricular dysfunction. Eur Cytokine Netw2004; 15(2): 139–144.
190.
CreemersEEJMCleutjensJPMSmitsJFM. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure?Circ Res2001; 89(3): 201–210.
191.
GearingABeckettPChristodoulouM. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature1994; 370: 555–557.
192.
SchönbeckUMachFLibbyP. Generation of biologically active IL-1β by matrix metalloproteinases: A novel caspase-1-independent pathway of IL-1β processing. J Immunol1998; 161: 3340–3346.
193.
TanJHuaQ. Correlations between serum inflammation factors and left ventricular remodeling in acute ST segment elevation myocardial infarction. Yonsei Med J2012; 53(3): 501–507.
194.
WebbCSBonnemaDDAhmedSH. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: Relation to left ventricular remodeling. Circulation2006; 114(10): 1020–1027.
195.
WagnerDRDelagardelleCErnensI. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail2006; 12(1): 66–72.
196.
KuliczkowskiWUrbaniakJHallénJ. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty. Kardiol Pol2013; 71(5): 31–36.
197.
CondeIDKleimanNS. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med2003; 348(25): 2575–2577.
198.
PusurogluHAkgulOErturkM. Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Coron Artery Dis2014; 25(7): 558–564.
199.
De BoerRAVoorsAAMuntendamP. Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail2009; 11(9): 811–817.
200.
SzadkowskaIWlazełRNMigałaM. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. Cardiol J2013; 20(6): 577–582.
201.
SzadkowskaIWlazelR. The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively. Biomarkers2013; 18(8): 655–659.
202.
WeirRAPetrieCJMurphyCA. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail2013; 6(3): 492–498.
WangJ-GWilliamsJCDavisBK. Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner. Blood2011; 118(8): 2366–2374.
205.
MallatZBenamerHHugelB. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation2000; 101(8): 841–843.
206.
MinP-KKimJ-YChungK-H. Local increase in microparticles from the aspirate of culprit coronary arteries in patients with ST-segment elevation myocardial infarction. Atherosclerosis2013; 227(2): 323–328.
207.
PortoIBiasucciLMDe MariaGL. Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. Eur Heart J2012; 33(23): 2928–2938.
208.
JungCSörenssonPSalehN. Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction. Atherosclerosis2012; 221(1): 226–231.
209.
PearsonTA. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation2003; 107(3): 499–511.
210.
BiasucciLMKoenigWMairJ. How to use C-reactive protein in acute coronary care. Eur Heart J2013; 34(48): 3687–3690.
211.
RidkerPDanielsonE. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med2008; 359(21): 2195–2207.
212.
RidkerPMThurenTZalewskiA. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J2011; 162(4): 597–605.
213.
Van TassellBWArenaRBiondi-ZoccaiG. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART Pilot Study). Am J Cardiol2013; 113(2): 321–327.
214.
SeropianIMToldoSVan TassellBW. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol2014; 63(16): 1593–1603.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
